Every so often a supplement arrives with a story so clean it feels inevitable: a single nutrient, quietly vanishing from the modern diet, whose absence helps explain a rising tide of diabetes, heart disease, and liver problems — and whose return could slow aging itself. That is the pitch for pentadecanoic acid, better known as C15:0, an odd-chain saturated fat found in butter and whole milk that one research group has branded the first new “essential fatty acid” discovered in nearly a century. The science behind it is genuinely intriguing: large studies following more than 170,000 people consistently link higher C15:0 levels to lower rates of type 2 diabetes, heart disease, and high blood pressure, and two small independent human trials have now shown it is safe and moves the right biomarkers. But it comes with two big asterisks. The most enthusiastic “essential nutrient” claims trace back to the scientist who co-founded the supplement company selling it, and no long-term human trial has yet proven C15:0 extends life. Here is what is real, what is promising, and what is still marketing.
📋 Simple Summary
C15:0 (pentadecanoic acid) is a saturated fat with an odd number of carbon atoms, found mainly in dairy fat and some fish. Unlike most saturated fats, which are linked to worse health, higher levels of C15:0 in the blood are consistently linked to better health — large studies of over 170,000 people find that people with more C15:0 have lower rates of type 2 diabetes, heart disease, and high blood pressure. Two small human trials show that taking 100–200 mg a day for 12 weeks is safe and produces modest improvements in liver enzymes, LDL cholesterol, and red-blood-cell markers. The catch: the claim that C15:0 is an “essential” longevity nutrient comes mostly from one researcher who co-founded the company selling it, the strongest cell studies are industry-funded, and no human trial has shown it extends lifespan. Our verdict: a promising 🥈 Silver compound with real but early human evidence — reasonable to try for metabolic health, worth watching closely, but not a proven longevity breakthrough.
The detailed breakdown continues below for those who want the full science.
Published: August 17, 2026
Evidence Tier: 🥈 Silver — large, consistent observational evidence plus two small independent human trials, but no long-term human proof of longevity, and the strongest “essentiality” claims are industry-linked and disputed
Category: Supplements & Compounds
⚖️ At a Glance: Pros & Cons
⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Talk to your doctor before taking any supplement. The information below is for education only.
✅ Pros (What the Evidence Supports)
- Strongest benefit: Lower type 2 diabetes risk — a meta-analysis of 95,810 adults found the top third of C15:0 blood levels had roughly 22–38% lower diabetes risk than the bottom third (PMID 32598176).
- Heart and blood-pressure support: In 172,891 people, higher odd-chain saturated fats like C15:0 were linked to 18% lower heart disease and 27% lower stroke risk (PMID 39365172).
- Early human trials are positive and safe: Two independent 12-week randomized trials found 100–200 mg/day improved liver enzymes, LDL cholesterol, and gut bacteria, with no serious side effects (PMID 39069269, PMID 38035997).
- Safety: A naturally occurring food fat with a long history of safe consumption in dairy; no adverse events were reported in the human trials.
❌ Cons (What the Evidence Doesn’t Support or Warns About)
- Biggest limitation: No long-term human trial shows C15:0 extends lifespan or improves hard outcomes — the benefit so far is biomarker-level, from 12-week studies of under 120 people combined.
- “Essential fatty acid” claim is disputed and industry-linked: The lead proponent co-founded the company selling C15:0 (Fatty15), and an independent review calls the “essential” label premature and “controversial” (PMID 39395658).
- Observational data can’t prove cause: Higher blood C15:0 is also simply a marker of eating dairy, so it may reflect an overall healthier diet rather than a direct effect of the fat itself.
- Who should avoid: Pregnant or breastfeeding women (unstudied), and anyone with a lipid disorder should talk to a doctor before deliberately adding a saturated-fat supplement.
What Is C15:0?
C15:0 is the shorthand for pentadecanoic acid, a saturated fatty acid with 15 carbon atoms in its chain. The “odd-chain” part matters: nearly all the fats in our food — palmitic acid (C16:0), stearic acid (C18:0), and the rest — have an even number of carbons. C15:0 and its close cousin C17:0 (heptadecanoic acid) are the two main odd-chain saturated fats, and they are rare, making up only a small slice of the fat in milk and ruminant meat (PMID 27422507).
Where does it come from? Three places:
- Dairy fat — butter, whole milk, cheese, and full-fat yogurt are the richest dietary sources, which is why C15:0 has long been used in research simply as a biomarker of how much dairy someone eats (PMID 25647578).
- Some fish and plants — smaller amounts appear in certain seafood and plant foods.
- Our own bodies and gut bacteria — gut microbes can make C15:0 from fiber, and the body can synthesize some internally through a process called alpha-oxidation, though how much this contributes is debated (PMID 27422507, PMID 37386075).
For decades, C15:0 was ignored as just a dairy marker. That changed when researchers noticed something odd: unlike every other saturated fat, higher C15:0 kept showing up alongside better health — the opposite of what saturated fat is “supposed” to do. That observation launched the current wave of interest, and the commercial product Fatty15 (100 mg/day of C15:0).
How It Works
The proposed mechanisms map directly onto the core biology of aging, which is why C15:0 has drawn longevity attention:
- Activates AMPK and inhibits mTOR. AMPK is the cell’s energy sensor (turned on by fasting and exercise); mTOR is the growth switch (turned off by calorie restriction and rapamycin). Cell studies show C15:0 activates AMPK and inhibits mTOR — the same two longevity pathways targeted by metformin and rapamycin (PMID 37960259). An independent study confirmed C15:0 drives glucose uptake in muscle cells through AMPK (PMID 33613155).
- Stabilizes cell membranes against “ferroptosis.” The “Cellular Stability Hypothesis” proposes that C15:0, being a straight, stable saturated fat, anchors cell membranes and protects them from a form of iron-driven cell death called ferroptosis — which is linked to type 2 diabetes, heart disease, and fatty liver (PMID 39057678).
- Shapes the gut microbiome. Certain bacteria (like Parabacteroides distasonis and Bacteroides acidifaciens) actually produce C15:0, and C15:0 in turn suppresses gut inflammation — creating a two-way street between this fat and the microbes that influence aging (PMID 37386075, PMID 39468026).
- Metabolizes into an endocannabinoid. C15:0 breaks down into pentadecanoylcarnitine, a newly identified “endocannabinoid-like” molecule that binds cannabinoid and serotonin receptors — a possible link to its proposed mood and sleep effects (PMID 35999445).
One important caveat: the most detailed mechanistic claims — the AMPK/mTOR comparison to rapamycin, the ferroptosis hypothesis, and the endocannabinoid work — come from the lab of Dr. Stephanie Venn-Watson, who co-founded Seraphina Therapeutics, the company that sells Fatty15. That does not make the data wrong, but it is a conflict of interest worth remembering whenever you read the strongest C15:0 claims (PMID 32424181, PMID 37960259, PMID 39057678).
The Longevity Connection
🩸 Metabolism and type 2 diabetes — the strongest evidence. This is where C15:0’s reputation is best grounded, and it is largely independent of the industry-linked lab. A 2021 meta-analysis of 33 prospective studies (95,810 adults, 19,904 diabetes cases) found the top third of C15:0 and C17:0 levels carried 22–38% lower type 2 diabetes risk (PMID 32598176). A 2025 analysis of the China Kadoorie Biobank plus 33 additional studies (112,193 participants) confirmed the pattern, finding a pooled 26% lower diabetes risk per higher C15:0 (PMID 40987456). A 2023 EPIC-InterAct study (11,124 diabetes cases) found low C17:0 levels were linked to a 55% higher diabetes incidence (PMID 37301794).
🫀 Heart and blood pressure — consistent but observational. The largest individual-participant analysis to date — 172,891 people across three European cohorts — found odd-chain saturated fats (like C15:0) were linked to 18% lower coronary heart disease and 27% lower stroke risk, in stark contrast to even-chain saturated fats, which raised risk (PMID 39365172). An NHANES analysis of 4,775 Americans found higher C15:0 was linked to 22% lower odds of hypertension (PMID 40542410). The one caveat: an earlier 2018 meta-analysis found the total cardiovascular benefit of C15:0 was weaker and not statistically significant for all outcomes (RR 0.94), with the clearest benefit in heart failure specifically (RR 0.72) (PMID 28001085) — a reminder that these are associations, not proof of cause.
🧪 Human trials — small but real. Two independent randomized trials, both published in 2024, are the reason this supplement graduated from “interesting biomarker” to “worth a look.” The first, from UC San Diego, gave 30 young adults with obesity 200 mg of C15:0 or placebo daily for 12 weeks: C15:0 blood levels rose significantly, and the people who reached the highest levels (above 5 µg/mL) saw meaningful drops in liver enzymes (ALT down 29 U/L) and a rise in hemoglobin — with no serious adverse events (PMID 39069269). The second, the TANGO trial, put 88 women with fatty liver disease on an Asian-adapted Mediterranean diet with or without C15:0: the C15:0 group lost the most weight (4.0 kg), reduced liver fat by 33%, and — uniquely to the C15:0 group — further lowered LDL cholesterol and boosted a beneficial gut bacterium (PMID 38035997). A secondary analysis even found reduced anxiety in the C15:0 group (PMID 40697557).
🧠 Brain — early and preclinical. The dolphin research that launched the C15:0 story found that, like humans, aging dolphins develop Alzheimer’s-like amyloid plaques, and C15:0 inhibited two brain targets involved in amyloid formation in cell assays (PMID 40332352). It is a fascinating parallel, but it is not human evidence.
⏳ Lifespan — the headline claim, unproven. The longevity pitch rests on the cell study showing C15:0 shares 24 anti-inflammatory, anti-fibrotic, and anticancer activities with rapamycin (PMID 37960259), plus the observation that people in Sardinia’s longevity zone carry more C15:0 (PMID 33650014). Those are suggestive. But there is no human trial — and no strong animal lifespan study — showing C15:0 extends life. “Activates the same pathways as rapamycin” is not the same as “makes you live longer like rapamycin.”
Key Studies
| Study | Design | Key Finding |
|---|---|---|
| Chen 2021 meta-analysis (PMID 32598176) | Meta-analysis, 33 cohorts (n=95,810) | Top vs. bottom third of C15:0/C17:0 linked to 22–38% lower type 2 diabetes risk. |
| Shi 2025 (PMID 39365172) | 3 cohorts, individual data (n=172,891) | Odd-chain SFAs linked to 18% lower CHD and 27% lower stroke; even-chain SFAs raised risk. |
| Sun 2025 (PMID 40987456) | China Kadoorie Biobank + meta (n=112,193) | Higher C15:0 linked to 28% lower heart disease and 26% lower diabetes risk. |
| Robinson 2024 (PMID 39069269) | RCT, double-blind (n=30, 200 mg/day, 12 wks) | Raised blood C15:0; top responders had ALT down 29 U/L and higher hemoglobin; no adverse events. |
| Chooi 2024 TANGO (PMID 38035997) | RCT, 3 arms (n=88 women with NAFLD, 12 wks) | C15:0 + Mediterranean diet cut liver fat 33%, further lowered LDL, and boosted Bifidobacterium adolescentis. |
| Venn-Watson & Schork 2023 (PMID 37960259) | Human cell-based assays (industry-affiliated) | C15:0 activated AMPK and inhibited mTOR, sharing 24 activities with rapamycin. |
| Fu 2021 (PMID 33613155) | Cell study (C2C12 myotubes, independent) | C15:0 promoted glucose uptake via the AMPK pathway, independent of insulin signaling. |
| Ciesielski 2024 (PMID 39395658) | Independent review (INRAE, France) | Calls C15:0’s “essential fatty acid” status premature and “controversial”; more study needed. |
| Chen 2025 (PMID 40542410) | Cross-sectional, NHANES (n=4,775) | Higher C15:0 linked to 22% lower odds of hypertension. |
Dosing and Safety
Human trials have used 100–200 mg per day, and this is the range that has published safety data:
| Context | Dose | Notes |
|---|---|---|
| Commercial product (Fatty15) | 100 mg/day | The standard OTC dose; sold as a C15:0 (pentadecanoic acid) capsule. |
| UC San Diego RCT (PMID 39069269) | 200 mg/day for 12 weeks | Highest studied dose; well tolerated with no serious adverse events. |
| TANGO trial (PMID 38035997) | C15:0 supplement daily for 12 weeks | Taken alongside a Mediterranean-style diet, not as a standalone. |
Form and timing: C15:0 is a fat, so take it with a meal containing some fat for best absorption. The studied form is pure C15:0 as a free fatty acid (the Fatty15 capsule); whole-food sources (butter, full-fat dairy) also raise C15:0 levels, but would require meaningful daily dairy intake to match a 100–200 mg supplement. There is no meaningful evidence that more is better — doses above 200 mg/day are essentially unstudied in humans.
Safety notes:
- Generally well tolerated. In the randomized trials, 200 mg/day for 12 weeks produced no serious adverse events, and C15:0 is a naturally occurring component of ordinary food (PMID 39069269).
- It is still a saturated fat. C15:0 itself appears neutral-to-favorable for cholesterol in the small trials, but this does not license loading up on butter; the trials used a purified supplement, not dairy fat.
- Long-term data is thin. Safety has only been tracked for 12 weeks in formal trials. Anyone planning to take it indefinitely is, to some degree, an early adopter.
- Interactions are largely unknown. Because C15:0 may influence metabolism and liver enzymes, tell your doctor if you take diabetes, cholesterol, or blood-pressure medication.
- Pregnancy and breastfeeding: No safety data — avoid.
❓ Common Questions About C15:0 (Pentadecanoic Acid)
What is C15:0 and how does it work?
C15:0 (pentadecanoic acid) is a saturated fat with an odd number of carbon atoms, found mainly in butter, whole milk, and some fish. It is thought to work by turning on AMPK (the cell’s energy sensor) and turning off mTOR (the growth switch) — the same two longevity pathways targeted by metformin and rapamycin — while also stabilizing cell membranes and shaping gut bacteria.
What does the evidence actually show?
The evidence is 🥈 Silver. Large observational studies (over 170,000 people) consistently link higher C15:0 to lower type 2 diabetes, heart disease, and high blood pressure, and two small 12-week human trials show it safely improves liver enzymes, LDL, and gut bacteria. But no long-term trial has shown it extends lifespan, and the strongest “essential nutrient” claims come from industry-linked research.
What’s the right dose?
The studied range is 100–200 mg per day, taken with a meal that contains some fat. The standard supplement dose is 100 mg/day (as in Fatty15), and a 200 mg/day dose was used in one clinical trial. There is no evidence that doses above 200 mg/day are better or safe.
What are the risks and side effects?
C15:0 appears very well tolerated; the human trials reported no serious side effects at 200 mg/day for 12 weeks. The main caveats are that it is a saturated fat (so it should not justify eating more butter), long-term safety beyond 12 weeks is unstudied, and interactions with diabetes, cholesterol, and blood-pressure medications are largely unknown.
Who should avoid it?
Pregnant or breastfeeding women should avoid C15:0 supplements because there is no safety data. Anyone with a lipid or cholesterol disorder, or taking diabetes, cholesterol, or blood-pressure medication, should talk to a doctor first. And anyone expecting a proven longevity “breakthrough” should know the lifespan claims are not yet backed by human evidence.
The Bottom Line
C15:0 is a genuinely interesting compound with a real, if early, evidence base. The observational data is unusually consistent for a supplement: across more than 170,000 people, higher C15:0 keeps showing up alongside lower type 2 diabetes, heart disease, and high blood pressure — the opposite pattern of every other saturated fat (PMID 32598176, PMID 39365172, PMID 40987456). And two small independent human trials, published in 2024, moved it from “interesting biomarker” to “safe and modestly effective”: 100–200 mg/day for 12 weeks improved liver enzymes, LDL cholesterol, and gut bacteria with no serious side effects (PMID 39069269, PMID 38035997). For a metabolically-healthy adult who already eats a decent diet, C15:0 at 100 mg/day is a reasonable, low-risk experiment.
The “longevity essential fatty acid” framing, however, is ahead of the evidence. The claim that C15:0 is the first new essential fatty acid in 90 years comes primarily from the researcher who co-founded the company selling it (PMID 32424181), and an independent review calls that “essential” label premature and controversial (PMID 39395658). The headline mechanism — “activates AMPK and inhibits mTOR like rapamycin” — rests on industry-linked cell studies, and activating a pathway is not the same as extending life. No human trial, and no strong animal study, has shown C15:0 makes anyone live longer.
Our verdict: 🥈 Silver for metabolic health, with a clear ⚠️ on the essentiality and longevity claims. Who it’s for: adults — especially 40+ — who want a well-tolerated, evidence-supported addition for metabolic and cardiovascular health, and who understand the data is early. Who it’s not for: anyone expecting a proven longevity breakthrough, pregnant or breastfeeding women, or anyone with a lipid disorder without medical guidance. If you take it: 100 mg/day with a fat-containing meal, treat it as a cautious experiment rather than a life-extension drug, and keep an eye on the follow-up trials — the next few years will tell us whether C15:0 is a genuine discovery or a well-marketed biomarker.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. C15:0 (pentadecanoic acid) is a dietary supplement and is not approved to treat, cure, or prevent any disease. Always consult a qualified healthcare provider before starting any supplement, especially if you are pregnant or breastfeeding, have a lipid or cholesterol disorder, or take diabetes, cholesterol, or blood-pressure medication. Read our full disclaimer →
Sources
- Pfeuffer M, Jaudszus A. Pentadecanoic and heptadecanoic acids: multifaceted odd-chain fatty acids. Adv Nutr. 2016. PMID 27422507
- Jenkins B, West JA, Koulman A. A review of odd-chain fatty acid metabolism and the role of pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) in health and disease. Molecules. 2015. PMID 25647578
- Liang J, et al. Biomarkers of dairy fat intake and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Crit Rev Food Sci Nutr. 2018. PMID 28001085
- Chen G, et al. Biomarkers of fatty acids and risk of type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Crit Rev Food Sci Nutr. 2021. PMID 32598176
- Shi F, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025. PMID 39365172
- Sun L, et al. Erythrocyte odd-chain fatty acids and the risk of cardiometabolic diseases: a prospective study and updated meta-analysis. Eur J Prev Cardiol. 2025. PMID 40987456
- Chen T, et al. Associations between serum pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) levels and hypertension: a cross-sectional analysis of NHANES data. Lipids Health Dis. 2025. PMID 40542410
- Lampousi AM, et al. Interaction between plasma phospholipid odd-chain fatty acids and GAD65 autoantibodies on the incidence of adult-onset diabetes: the EPIC-InterAct case-cohort study. Diabetologia. 2023. PMID 37301794
- Robinson MK, et al. Pentadecanoic acid supplementation in young adults with overweight and obesity: a randomized controlled trial. J Nutr. 2024. PMID 39069269
- Chooi YC, et al. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. Am J Clin Nutr. 2024. PMID 38035997
- Salamanca-Sanabria A, et al. Potential effects of Asian-adapted Mediterranean diet in depression and anxiety among women with metabolic dysfunction-associated steatotic liver disease. Front Nutr. 2025. PMID 40697557
- Fu WC, et al. Pentadecanoic acid promotes basal and insulin-stimulated glucose uptake in C2C12 myotubes. Food Nutr Res. 2021. PMID 33613155
- Venn-Watson S, Lumpkin R, Dennis EA. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Sci Rep. 2020. PMID 32424181
- Venn-Watson S, Schork NJ. Pentadecanoic acid (C15:0), an essential fatty acid, shares clinically relevant cell-based activities with leading longevity-enhancing compounds. Nutrients. 2023. PMID 37960259
- Venn-Watson S. The cellular stability hypothesis: evidence of ferroptosis and accelerated aging-associated diseases as newly identified nutritional pentadecanoic acid (C15:0) deficiency syndrome. Metabolites. 2024. PMID 39057678
- Ciesielski V, Legrand P, Blat S, Rioux V. New insights on pentadecanoic acid with special focus on its controversial essentiality: a mini-review. Biochimie. 2024. PMID 39395658
- Wei W, et al. Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid. Nat Microbiol. 2023. PMID 37386075
- Wu Y, et al. Galactooligosaccharides and Limosilactobacillus reuteri synergistically alleviate gut inflammation and barrier dysfunction by enriching Bacteroides acidifaciens for pentadecanoic acid biosynthesis. Nat Commun. 2024. PMID 39468026
- Manca C, et al. Circulating fatty acids and endocannabinoidome-related mediator profiles associated to human longevity. GeroScience. 2021. PMID 33650014
- Venn-Watson S, Jensen ED. Aging-associated amyloid-β plaques and neuroinflammation in bottlenose dolphins. Int J Mol Sci. 2025. PMID 40332352